This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
PBMs are companies that serve as the controversial middlemen of drugpricing negotiations, and of the four largest, two are owned by Cigna and Humana. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.
Our reporters Olivia Goldhill and Meghana Keshavan will be live-blogging the meeting all day — tune in here. It’s a critical meeting — MDMA could be the first Schedule I psychedelic to be deemed to have a medical use. Read the rest…
Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drugprices keep dropping My $0.02 Autumn is here!
In a year of major change and outstanding questions, growing scrutiny on patent protection and drugpricing, and uncertainty around global price control measures and the Inflation Reduction Act, understanding the implications of new leadership and emerging mandates is critical. FDA Law Blog is a conference media partner.
NHC Medicare DrugPrice Negotiation Program Comments April 27, 2023 By: Allen Pinn, Coordinator, Policy April 14, the National Health Council (NHC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the Medicare DrugPrice Negotiation Program, established under the Inflation Reduction Act.
On September 18-20, Informa Connect will hold its annual #MDRPSummit in Chicago (and via livestream) to discuss the complex, ever-evolving laws and regulations in the government pricing and price reporting space. FDA Law Blog readers can receive a 10% discount off the conference registration price.
Understanding pharmacy benefit management and drugpricing The U.S. prescription drug supply chain is extraordinarily complex. It captures, with strong simplification, the web of stakeholders in the prescription drug market and the myriad of contractual agreements that drives the cash flows between them.
However, growing concerns about drugpricing, misleading claims, and overprescription have led policymakers to consider banning pharma ads from television altogether. SEO-optimized blog content helps brands rank higher in search results. Without TV ads, pharma marketers must pivot toward alternative channels.
Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drugpricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.
Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drugprice negotiations.
NHC Comments on Request for Information: Medicare Transaction Facilitator (MTF) for the Medicare DrugPrice Negotiation Program (PDF) November 13, 2023 Benjamin Stidham, Contract Specialist Centers for Medicare & Medicaid Services U.S. The right to encryption: privacy as preventing unlawful access.
Even though the PTE provisions established in the DrugPrice Competition and Patent Restoration Act are forty-plus years old, courts are still grappling with questions about how to best implement the Patent Term Extension.
Rutta Chief Executive Officer The post NHC Comments on Information Collection Request for DrugPrice Negotiation by IRA appeared first on National Health Council. Created by and for patient organizations over 100 years ago, the NHC brings diverse organizations together to forge consensus and drive patient-centered health policy.
Our people are never affected by the hospital charges or doctors’ fees but they experience a volcanic impact by the fuel prices and drugprices. To bring down the cost of treatment, we are all out to fight for the allopathic drugprices, I think it may be possible, otherwise how the 10 to 90 per cent discount is offered.
Hatch Foundation’s For cheap generic drugprices, you can thank 40 years of Hatch-Waxman We Work For Health’s Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem Tradeoffs’ Race to the Bottom Series FDA CDER Conversations – 40th Anniversary of the Generic Drug Approval Pathway The U.S.
Other Blogs: What You Need to Know about Celiac Disease 05/01/2023 Read More NHC Medicare DrugPrice Negotiation Program Comments 04/27/2023 Read More Minority Health: The Importance of Patient Navigation and Access to Timely Care 04/25/2023 Read More The post What You Need to Know about Celiac Disease appeared first on National Health Council.
Fein will share his latest thinking on a wide range of topics, including: The prescription market in 2022 Benefit design and plan sponsor strategies Federal and state drugpricing policy The 340B DrugPricing Program Consolidation and vertical integration Specialty pharmacy trends Copay accumulators, maximizers, and utilization management tools Biosimilars (..)
Medicare DrugPrice Negotiation Program The rising costs of prescription drugs has consistently been an area of concern for patients and for the financial health of Medicare. The Roundtable identified lessons learned that can be used to inform future listening sessions and CMS’ broader patient engagement strategies.
Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToS
Medicare DrugPrice Negotiation Program The rising costs of prescription drugs has consistently been an area of concern for patients and for the financial health of Medicare. The Roundtable identified lessons learned that can be used to inform future listening sessions and CMS’ broader patient engagement strategies.
The NHC looks forward to exploring future discussion and collaboration with these organizations and others in this field, including organizations representing active military, to advance our shared priorities on patient engagement and access to affordable and equitable health care.
General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare DrugPrice Negotiation Program (DPNP). This includes collecting data on utilization management practices, formulary changes, and patient experiences.
What we find challenging is that drugpricing discussions often sidestep the core issues in today’s complex health care system in the U.S. While our program represents a major step forward in improving access to our medicines, our work on behalf of patients is far from done — but we can’t fix the entire system alone.
Perhaps unsurprisingly given the extraordinary focus on drugpricing in the last decade, generic competition—FDA’s only real way to have an effect on drugpricing—tops this year’s list.
Individuals who choose a new plan will see changes to their coverage beginning January 1, 2025. This year’s Open Enrollment is marked by significant changes from the recent prescription drugpricing law. To learn more about Open Enrollment, visit Medicare.gov.
Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drugprices increase faster than the rate of inflation must pay additional per-unit rebates to the program. We previously blogged on the district court’s decision last year. Vanda Pharmaceuticals, Inc. Centers for Medicare and Medicaid Servs.,
If you have any questions about the NHC’s policy priorities or 2023 policy matrix, please contact Eric Gascho , Senior Vice President, Policy and Government Affairs.
Other Blogs: Introducing NHC Connect’s Newest Member Resource: AI Connect! Together, let’s build a vibrant Health AI community that pushes the boundaries of what’s possible, while always putting patients first.
The 340B DrugPricing Program remains highly controversial. Read on for full details on pricing and registration. Fein will help you and your team stay on top of the current trends and market developments. PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions.
In this blog post, we will discuss the evolution of DIR fees leading up to the DIR fee changes coming in 2024, and the pros and cons independent pharmacies owners should prepare for. These fees are based on a variety of factors, including performance metrics and drugprices, and are typically calculated retroactively.
Excessive IPR protection can lead to exorbitant drugprices, making life-saving medications inaccessible to millions of people, particularly in developing countries like India. A strong IPR regime can attract foreign investment, create jobs, and position India as a global leader in the pharmaceutical sector.
The PERA Act would not only minimize these benefits of § 101, but it would make it easier for brand-name biologic companies to obtain less innovative patents, leading to higher drugprices. The PERA Act would abolish § 101’s careful test for eligibility and would open the floodgates to non-innovative patents. Who you ask?
Significant initiatives being undertaken by CMS and OPOLE include behavioral health, drugprice affordability, maternity care, Medicaid unwinding, and rural health. Hammarlund also highlighted CMS’ ongoing efforts to expand coverage and advance health equity through the policymaking and implementation processes.
What we find challenging is that drugpricing discussions often sidestep the core issues in today’s complex health care system in the U.S. While our program represents a major step forward in improving access to our medicines, our work on behalf of patients is far from done — but we can’t fix the entire system alone.
Kirschenbaum — As we and others closely following drugpricing have predicted, multiple additional lawsuits have followed in the wake of Merck’s challenge to the Inflation Reduction Act (IRA) price negotiation provisions in the D.C. By Faraz Siddiqui & Alan M. federal district court on June 6 (see our post here ).
They have been staples of cancer treatment for decades, according to a White House blog post , but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.
Other Blogs: CEO Update: 2023 Offers Opportunity for the Patient Community 05/04/2023 Read More What You Need to Know about Celiac Disease 05/01/2023 Read More NHC Medicare DrugPrice Negotiation Program Comments 04/27/2023 Read More The post CEO Update: 2023 Offers Opportunity for the Patient Community appeared first on National Health Council.
Other Blogs: NHC Legislative Health Care Update 05/30/2023 Read More The Time is Now for Bold Action on Asthma and Allergies 05/25/2023 Read More Guest Post: Why Struggle?
Not only will this precipitate into lower treatment costs and ensure equitable biopharma access for Indian patients, but could also peg Indian pharma companies to become global market leaders in the biosimilars segment and effect a major change in drugpricing standards. appeared first on Express Pharma.
Pulses is a scholarly blog supported by a team of pharmacy education scholars. When we step back and think about these situations as an educator, it may be easy to overlook the large cognitive load imposed by learning this large amount of information all at once. Jaclyn is very active in professional organizations.
We’ve expressed our own strong opinions on the topic in several blog posts, including this one. To learn how two hospitals we serve do just that, Click Here to read our blog post, “How To Manage A Director of Pharmacy’s Responsibilities And An Optimized 340B Program. Without Hiring More Staff.”
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content